CONMED (CNMD) – Investment Analysts’ Recent Ratings Changes

CONMED (NYSE: CNMD) has recently received a number of price target changes and ratings updates:

• 3/29/2026 – CONMED was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 3/21/2026 – CONMED was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 3/18/2026 – CONMED was upgraded by Wells Fargo & Company to “hold”.
• 3/17/2026 – CONMED was downgraded by Piper Sandler from “overweight” to “neutral”. They now have a $39.00 price target on the stock, down from $55.00.
• 3/7/2026 – CONMED was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 2/21/2026 – CONMED was upgraded by Wall Street Zen from “hold” to “buy”.
• 2/3/2026 – CONMED was upgraded by Zacks Research from “strong sell” to “hold”.

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.